American Research Journal of Biomedical Engineering

Aim: This study calculated the effects on creatine phosphokinase (CPK) levels, after treatment with either of 2 drugs: the erythropoietin (Epo) and the antioxidant lazaroid (L) drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the certain influence, after the respective drug usage in an induced ischemia reperfusion (IR) animal experiment. Materials and Methods: The 2 main experimental endpoints at which the serum CPK levels (CPKl) were evaluated was the 60th reperfusion min (for the groups A, C and E) and the 120th reperfusion min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after the L administration. Results: The first preliminary study of Epo presented a non significant hyperkinase mice ffect by 2.08%+2.77% (p-value=0.4430). The second preliminary study of U-74389G presented a significant hyperkinasemic effect by 8.52%+4.35% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that L is 4.09626-fold [4.092989 - 4.099534] more hyperkinasemic than Epo (p-value=0.0000). Conclusions: The anti-oxidant capacities of U-74389G ascribe 4.09626-fold more hyperkinasemic effects than Epo (p-value=0.0000)